Candel Therapeutics, Inc.
CADLNasdaqCIK 1841387HealthcareFiscal year ends Dec 31
Reports and events: 119 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-1012:16 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-387310 |
| 2026-09-0920:50 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-386561 |
| 2026-08-1312:30 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-347980 |
| 2026-08-1312:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-347957 |
| 2026-06-2420:24 ET | 8-K | 5.07 Shareholder vote results | 0001841387-26-000009 |
| 2026-06-1620:23 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001841387-26-000007 |
| 2026-05-1520:13 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-226751 |
| 2026-05-1412:30 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-222904 |
| 2026-05-1412:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-222892 |
| 2026-04-2920:05 ET | DEF 14A | Proxy statementPeriod 2026-06-23 | 0001193125-26-191506 |
| 2026-03-1820:23 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001494695-26-000005 |
| 2026-03-1212:17 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-103134 |
| 2026-03-1212:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-103126 |
| 2026-02-2313:00 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-062490 |
| 2026-02-1921:03 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-059334 |
| 2025-12-0513:30 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-308719 |
| 2025-11-1313:30 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-279086 |
| 2025-11-1313:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-279072 |
| 2025-10-1412:21 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-238254 |
| 2025-08-2120:30 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0000950170-25-110682 |
| 2025-08-1412:10 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-108450 |
| 2025-08-1412:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-108448 |
| 2025-06-2413:27 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-145405 |
| 2025-06-2312:15 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-144204 |
| 2025-06-1812:30 ET | 8-K | 5.07 Shareholder vote results | 0000950170-25-087696 |
| 2025-06-0612:11 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-082705 |
| 2025-05-2812:10 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-078079 |
| 2025-05-2221:12 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-076458 |
| 2025-05-1312:30 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-069833 |
| 2025-05-1312:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-069826 |
| 2025-04-2920:05 ET | DEF 14A | Proxy statementPeriod 2025-06-17 | 0000950170-25-060093 |
| 2025-04-2320:15 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-057398 |
| 2025-03-2701:57 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-064374 |
| 2025-03-1320:30 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-038803 |
| 2025-03-1320:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-038757 |
| 2025-02-2513:15 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-026100 |
| 2025-01-1313:05 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-004581 |
| 2024-12-1322:30 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-278717 |
| 2024-12-1112:45 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-274870 |
| 2024-11-1413:30 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-126767 |
| 2024-11-1413:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-126759 |
| 2024-10-2812:30 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-117578 |
| 2024-08-1312:30 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-095784 |
| 2024-08-1312:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-095775 |
| 2024-06-2812:39 ET | 8-K | 5.07 Shareholder vote results | 0000950170-24-078795 |
| 2024-05-3020:30 ET | DEF 14A | Proxy statementPeriod 2024-06-26 | 0001193125-24-150379 |
| 2024-05-3020:15 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0000950170-24-066608 |
| 2024-05-2321:05 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-064022 |
| 2024-05-1412:30 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-059118 |
| 2024-05-1412:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-059109 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.